MPLN Presents NGS Workshop at 13th International Conference on Pathology and Molecular Diagnostics

Posted on June 23 2017 by J Seabrook

San Diego June 27th is host to Dr. Tandon's workshop on contemporary genomic studies in hematologic pathology: Utility of next generation sequencing in clinical evaluation of myeloid and lymphoid malignancies.

Next generation sequencing…
Read more

MPLN expands oncology offering with Next Generation Sequencing based mutation panels for evaluation

Posted on May 18 2017 by J Seabrook

Myeloproliferative neoplasms (MPNs) are characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute leukemia.  Clinical data and practice guidelines have evolved at a rapid pace for this heterogeneous…
Read more

Laboratory Developed Tests Roadmap and IVD Vendors

Posted on December 13 2016 by J Seabrook

MPLN follows a development process for laboratory developed tests. A phased approach is useful for organizing and assessing the performance of an assay. 

Read more


MPLN presents IgVH NGS at AMP 2016

Posted on November 21 2016 by J Seabrook

Genomics team members from MPLN, Inc. including Isabel Hubbard, M.Sc., and Drs. Alice Layton and Bevan Tandon recently presented at the 2016 Association for Molecular Pathology annual meeting on the relative utility of Next Generation Sequencing for…
Read more

MPLN attending AMP 2016 showcasing IgVH SHM by NGS

Posted on November 10 2016 by J Seabrook

Meet MPLN's Dr. Bevan Tandon at Poster H50 for discussions on IgVH Somatic Hypermutation (SHM) by NGS.

Using a next generation sequencing-based approach to IgVH SHM detection, the MPLN methodology utilizes patient DNA as a sample starting…
Read more

1 2 3